Royalty Pharma to Present at Upcoming Investor Conferences

Rhea-AI Summary

Royalty Pharma plc (Nasdaq: RPRX) will participate in three investor conferences in May 2021: the Bank of America 2021 Healthcare Conference on May 12, the Truist Securities Life Sciences Summit on May 20, and the UBS Global Healthcare Virtual Conference on May 24. All events will be accessible via the company’s Events page, and webcasts will be archived for at least thirty days.

Royalty Pharma is a leading buyer of biopharmaceutical royalties, funding innovation in the industry and holding royalties on over 45 commercial products.

NEW YORK, May 07, 2021 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced that it will participate in the following upcoming investor conferences during the month of May:

• Bank of America 2021 Healthcare Conference on Wednesday, May 12 at 9:30 a.m. EDT
• 7^th Annual Truist Securities Life Sciences Summit on Thursday, May 20 at 11:00 a.m. EDT
• UBS Global Healthcare Virtual Conference on Monday, May 24 at 2:00 p.m. EDT
  

The webcasts will be accessible from Royalty Pharma’s “Events” page at https://www.royaltypharma.com/investors/news-and-events/events. Webcasts will also be archived for a minimum of thirty days.

About Royalty Pharma plc

Founded in 1996, Royalty Pharma is the largest buyer of biopharmaceutical royalties and a leading funder of innovation across the biopharmaceutical industry, collaborating with innovators from academic institutions, research hospitals and not-for-profits through small and mid-cap biotechnology companies to leading global pharmaceutical companies. Royalty Pharma has assembled a portfolio of royalties which entitles it to payments based directly on the top-line sales of many of the industry’s leading therapies. Royalty Pharma funds innovation in the biopharmaceutical industry both directly and indirectly - directly when it partners with companies to co-fund late-stage clinical trials and new product launches in exchange for future royalties, and indirectly when it acquires existing royalties from the original innovators. Royalty Pharma’s current portfolio includes royalties on more than 45 commercial products, including AbbVie and J&J’s Imbruvica, Astellas and Pfizer’s Xtandi, Biogen’s Tysabri, Gilead’s Trodelvy, Merck’s Januvia, Novartis’ Promacta, and Vertex’s Kalydeco, Orkambi, Symdeko and Trikafta, and five development-stage product candidates. For more information, visit www.royaltypharma.com.

Royalty Pharma Investor Relations and Communications

+1 (212) 883-6772
ir@royaltypharma.com

FAQ

What investor conferences will Royalty Pharma (RPRX) attend in May 2021?

Royalty Pharma will attend the Bank of America Healthcare Conference on May 12, the Truist Securities Life Sciences Summit on May 20, and the UBS Global Healthcare Virtual Conference on May 24.

How can I access the webcasts for Royalty Pharma's upcoming conferences?

The webcasts for Royalty Pharma's conferences can be accessed from their Events page on their website.

What is Royalty Pharma's business focus?

Royalty Pharma specializes in buying biopharmaceutical royalties and funding innovation in the biopharmaceutical industry.

What products are included in Royalty Pharma's portfolio?

Royalty Pharma's portfolio includes royalties on over 45 commercial products, such as Imbruvica, Xtandi, and Tysabri.

When will the webcasts from Royalty Pharma's conferences be available?

The webcasts will be archived for a minimum of thirty days after the events.